Compare Aurora Cannabis Inc (ACB) vs iShares Core S&P 500 ETF (IVV) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

IVV, tracking the S&P 500, trades at $754.80, up 0.87% with a bullish technical signal from moving averages. The ETF shows strong institutional backing with $886 billion in assets and a low 0.03% expense ratio. Recent sector rotation has pressured tech stocks, but broader market optimism persists with analysts targeting S&P 500 levels up to 8,800 by year-end.

The outlook remains positive given strong earnings growth expectations and reasonable valuations, though concentration risk in top holdings and potential summer volatility pose near-term challenges. IVV offers efficient exposure to US large-caps, with dividend distributions providing additional return potential for long-term investors.